Novartis AG (NVS) states Rare Muscle Disease Drug Shows Promise in Early Trial

Novartis AG (NYSE:NVS) is among the Best Pharmaceutical Stocks.

On June 11, Novartis AG (NYSE:NVS) reported that an experimental drug acquired through its $12 billion Avidity Biosciences deal showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy. Del-brax lowered two disease-linked blood markers and reduced signs of muscle damage in patients with the genetic disorder. The company said the therapy may become the first disease-modifying treatment for FSHD. It is a condition affecting an estimated 45,000 to 87,000 people in the US and EU. The firm also noted its safety profile remained consistent with prior results, and a late-stage study is now enrolling patients.

Separately, Reuters reported on May 31 that  Novartis AG (NYSE:NVS) said early data from an actinium-based radiopharma drug had anti-tumor activity in advanced prostate cancer. It included PSA reductions in a 101-patient study, with more than 85% response in untreated patients and 52.5% in those previously treated with Pluvicto. Chief Medical Officer Shreeram Aradhye said larger trials are needed to assess side effects. TD Cowen analysts flagged dry mouth and severe anemia as major risks and noted the corporation is advancing two late-stage studies, along with expanding isotope supply planning.

 Novartis AG (NYSE:NVS) is a holding company that works in the business of developing, manufacturing, and marketing healthcare products.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.